PDF DatasheetHuman Anti-CD30 / TNFRSF8 Antibody Product Attributes
CD30 / TNFRSF8 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD30 / TNFRSF8 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of CD30 / TNFRSF8 could be seen inlymphoid tissue in appendix, non-germinal center cells in the lymph node, germinal center cells in the tonsil and non-germinal center cells in the tonsil. We were unable to detect CD30 / TNFRSF8 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD30 / TNFRSF8 expression as measured by anti-CD30 / TNFRSF8 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | + | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – |
| TNFRSF8 Variability | + | + | ++ | + | ++ | + | +++ | + | ++ | ++ | ++ | ++ | + | + | + | ++ | + | ++ | ++ | ++ |
| CD30 / TNFRSF8 General Information | |
|---|---|
| Alternate Names | |
| CD30, TNFRSF8 | |
| Molecular Weight | |
| 105-120kDa | |
| Chromosomal Location | |
| 1p36.22 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TNFRSF8 |
| Entrez Gene ID | 943 |
| Ensemble Gene ID | ENSG00000120949 |
| RefSeq Protein Accession(s) | NP_001268359, NP_001234, XP_011540743, XP_011540745 |
| RefSeq mRNA Accession(s) | NM_152942, XM_011542443, NM_001281430, XM_011542441 NM_001243 |
| RefSeq Genomic Accession(s) | NC_000001, NG_029573, NC_018912, |
| UniProt ID(s) | A5D8T4, P28908 |
| UniGene ID(s) | A5D8T4, P28908 |
| HGNC ID(s) | 11923 |
| Cosmic ID(s) | TNFRSF8 |
| KEGG Gene ID(s) | hsa:943 |
| PharmGKB ID(s) | PA36616 |
| General Description of CD30 / TNFRSF8. | |
| Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. Its epitope is located between aa112-412. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin, multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T, B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies, lymphomas derived from resting, precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). | |
There are no reviews yet.